137 related articles for article (PubMed ID: 17639050)
1. The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
Kato S; Sadarangani A; Lange S; Villalón M; Brañes J; Brosens JJ; Owen GI; Cuello M
Endocr Relat Cancer; 2007 Jun; 14(2):351-68. PubMed ID: 17639050
[TBL] [Abstract][Full Text] [Related]
2. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.
Sadarangani A; Kato S; Espinoza N; Lange S; Llados C; Espinosa M; Villalón M; Lipkowitz S; Cuello M; Owen GI
Apoptosis; 2007 Jan; 12(1):73-85. PubMed ID: 17136491
[TBL] [Abstract][Full Text] [Related]
3. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
[TBL] [Abstract][Full Text] [Related]
4. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
6. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
8. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
[TBL] [Abstract][Full Text] [Related]
9. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
11. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
12. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
14. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
15. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2.
Jung YH; Lim EJ; Heo J; Kwon TK; Kim YH
Int J Oncol; 2012 Jun; 40(6):1941-8. PubMed ID: 22426894
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death.
Li J; Sharkey CC; King MR
Sci Rep; 2015 May; 5():9987. PubMed ID: 25984950
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
19. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
Int J Oncol; 2015 Aug; 47(2):506-16. PubMed ID: 26044191
[TBL] [Abstract][Full Text] [Related]
20. TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells.
Heijink DM; Jalving M; Oosterhuis D; Sloots IA; Koster R; Hollema H; Kleibeuker JH; Koornstra JJ; de Vries EG; de Jong S
J Pathol; 2011 Feb; 223(3):378-89. PubMed ID: 21171083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
